MULTIPLE MYELOMA MONITORING PANEL Test
Test Cost: AED 1990.0
Symptoms, Diagnosis, and Referring Details
Test Name: MULTIPLE MYELOMA MONITORING PANEL Test
Components:
- CBC
- Urea
- Creatinine
- Calcium, total
- Albumin
- LDH
- Beta 2 Microglobulin
- Protein electrophoresis, serum
- Immunotyping, serum
- Kappa / Lambda Light Chains Free, serum
- Immunoglobulin Profile, serum
Price: 1990.0 AED
Sample Condition: 3 mL (2 mL min.) whole blood in 1 Lavender Top (EDTA) tube AND 5 mL (3 mL min.) serum from 1 SST. Ship refrigerated. DO NOT FREEZE.
Report Delivery: Sample daily by 9 am; report next working day
Method: Capillary electrophoresis, Agarose Gel Electrophoresis, Immunoturbidimetry, CLIA Spectrophotometry, Electrical impedence, VCS Nephelometry
Test Type: Multiple Myeloma
Doctor: Oncologist
Test Department:
Pre Test Information: No special preparation required
Test Details
The Multiple Myeloma Monitoring Panel test is a diagnostic tool used to monitor and assess the progression of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. This panel includes several tests that provide valuable information about the disease status and response to treatment.
The tests included in the Multiple Myeloma Monitoring Panel may vary depending on the specific laboratory or healthcare provider, but typically include:
- Complete Blood Count (CBC): This test measures the levels of different blood cells, including red blood cells, white blood cells, and platelets. It helps to evaluate the overall health of the patient and detect any abnormalities.
- Serum Protein Electrophoresis (SPEP): This test separates the proteins in the blood and measures their levels. It helps to identify abnormal proteins, such as monoclonal proteins, which are often present in multiple myeloma.
- Serum Immunofixation Electrophoresis (IFE): This test is used to confirm the presence of monoclonal proteins detected in the SPEP. It helps to determine the type and amount of abnormal proteins present.
- Serum Free Light Chain Assay (FLC): This test measures the levels of kappa and lambda light chains, which are components of immunoglobulins produced by plasma cells. It helps to evaluate the function of plasma cells and detect any abnormalities.
- Beta-2 Microglobulin: This test measures the levels of a protein called beta-2 microglobulin, which is often elevated in multiple myeloma. It helps to assess the disease stage and prognosis.
- Urine Protein Electrophoresis (UPEP): This test measures the levels of proteins in the urine and helps to identify abnormal proteins, such as Bence Jones proteins, which are often present in multiple myeloma.
- Bone Marrow Biopsy: This procedure involves the removal of a small sample of bone marrow for examination under a microscope. It helps to evaluate the number and characteristics of plasma cells and determine the extent of bone marrow involvement.
These tests are typically performed at regular intervals to monitor the disease progression, assess the response to treatment, and detect any relapse or recurrence of multiple myeloma. The results of the Multiple Myeloma Monitoring Panel are used by healthcare providers to make informed decisions regarding the management and treatment of the disease.
Test Name | MULTIPLE MYELOMA MONITORING PANEL Test |
---|---|
Components | *CBC *Urea *Creatinine *Calcium, total *Albumin *LDH*Beta 2 Microglobulin *Protein electrophoresis, serum*Immunotyping, serum*Kappa / Lambda Light Chains Free, serum *Immunoglobulin Profile, serum |
Price | 1990.0 AED |
Sample Condition | 3 mL (2 mL min.) whole blood in 1 Lavender Top (EDTA) tube AND 5 mL (3 mL min.) serum from 1 SST. Ship refrigerated. DO NOT FREEZE. |
Report Delivery | Sample Daily by 9 am; Report Next Working day |
Method | Capillary electrophoresis,Agarose Gel Electrophoresis, Immunoturbidimetry,CLIASpectrophotometry, Electrical impedence, VCSNephelometry |
Test type | Multiple Myeloma |
Doctor | Oncologist |
Test Department: | |
Pre Test Information | No special preparation required |
Test Details |
The Multiple Myeloma Monitoring Panel test is a diagnostic tool used to monitor and assess the progression of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. This panel includes several tests that provide valuable information about the disease status and response to treatment. The tests included in the Multiple Myeloma Monitoring Panel may vary depending on the specific laboratory or healthcare provider, but typically include: 1. Complete Blood Count (CBC): This test measures the levels of different blood cells, including red blood cells, white blood cells, and platelets. It helps to evaluate the overall health of the patient and detect any abnormalities. 2. Serum Protein Electrophoresis (SPEP): This test separates the proteins in the blood and measures their levels. It helps to identify abnormal proteins, such as monoclonal proteins, which are often present in multiple myeloma. 3. Serum Immunofixation Electrophoresis (IFE): This test is used to confirm the presence of monoclonal proteins detected in the SPEP. It helps to determine the type and amount of abnormal proteins present. 4. Serum Free Light Chain Assay (FLC): This test measures the levels of kappa and lambda light chains, which are components of immunoglobulins produced by plasma cells. It helps to evaluate the function of plasma cells and detect any abnormalities. 5. Beta-2 Microglobulin: This test measures the levels of a protein called beta-2 microglobulin, which is often elevated in multiple myeloma. It helps to assess the disease stage and prognosis. 6. Urine Protein Electrophoresis (UPEP): This test measures the levels of proteins in the urine and helps to identify abnormal proteins, such as Bence Jones proteins, which are often present in multiple myeloma. 7. Bone Marrow Biopsy: This procedure involves the removal of a small sample of bone marrow for examination under a microscope. It helps to evaluate the number and characteristics of plasma cells and determine the extent of bone marrow involvement. These tests are typically performed at regular intervals to monitor the disease progression, assess the response to treatment, and detect any relapse or recurrence of multiple myeloma. The results of the Multiple Myeloma Monitoring Panel are used by healthcare providers to make informed decisions regarding the management and treatment of the disease. |